Time filter

Source Type

Ymittos Athens, Greece

Ditsos I.,National and Kapodistrian University of Athens | Tsamakis C.,Attikon Hospital | Gregoriou S.,National and Kapodistrian University of Athens | Rigopoulos D.,National and Kapodistrian University of Athens
Anais Brasileiros de Dermatologia | Year: 2013

Skin metastases from colorectal carcinoma are rare and signal advanced disease. We present a case of an 80-year-old male with a large skin metastatic focus in the lower abdomen, a year after resection of a colonic ade-nocarcinoma. The patient had already finished receiving his first cycle of chemotherapy shortly before the discovery of the abdominal nodules and at the same period a chest X-ray, revealed shadows at the base of the right lung. © 2013 by Anais Brasileiros de Dermatologia. Source

Ruppe E.,University Paris Diderot | Ruppe E.,Laboratoire Of Bacteriologie | Lixandru B.,Cantacuzino Institute | Cojocaru R.,National Center for Preventive Medicine | And 18 more authors.
Antimicrobial Agents and Chemotherapy | Year: 2013

Extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli (ESBL E. coli) strains are of major concern because few antibiotics remain active against these bacteria. We investigated the association between the fecal relative abundance (RA) of ESBL-producing E. coli (ESBL-RA) and the occurrence of ESBL E. coli urinary tract infections (UTIs). The first stool samples passed after suspicion of UTI from 310 women with subsequently confirmed E. coli UTIs were sampled and tested for ESBL-RA by culture on selective agar. Predictive values of ESBL-RA for ESBL E. coli UTI were analyzed for women who were not exposed to antibiotics when the stool was passed. ESBL E. coli isolates were characterized for ESBL type, phylogroup, relatedness, and virulence factors. The prevalence of ESBL E. coli fecal carriage was 20.3%, with ESBL E. coli UTIs being present in 12.3% of the women. The mean ESBL-RA (95% confidence interval [CI]) was 13-fold higher in women exposed to antibiotics at the time of sampling than in those not exposed (14.3% [range, 5.6% to 36.9%] versus 1.1% [range, 0.32% to 3.6%], respectively; P<0.001) and 18-fold higher in women with ESBL E. coli UTI than in those with another E. coli UTI (10.0% [range, 0.54% to 100%] versus 0.56% [range, 0.15% to 2.1%[, respectively; P<0.05). An ESBL-RA of<0.1% was 100% predictive of a non-ESBL E. coli UTI. ESBL type, phylogroup, relatedness, and virulence factors were not found to be associated with ESBL-RA. In conclusion, ESBL-RA was linked to the occurrence of ESBL E. coli UTI in women who were not exposed to antibiotics and who had the same clone of E. coli in urine samples and fecal samples. Especially, a low ESBL-RA appeared to be associated with a low risk of ESBL E. coli infection. Copyright © 2013, American Society for Microbiology. All Rights Reserved. Source

Vassilakopoulou M.,Royal Marsden Hospital | Psyrri A.,Attikon Hospital | Argiris A.,Hygeia Hospital | Argiris A.,University of Texas Health Science Center at San Antonio
Oral Oncology | Year: 2015

Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC. © 2015 Elsevier Ltd. All rights reserved. Source

Papakonstantinou O.,Attikon Hospital | Drakonaki E.E.,University of Crete | Maris T.,University of Crete | Vasiliadou A.,Thalassemia Unit | And 2 more authors.
Abdominal Imaging | Year: 2015

Purpose: Splenomegaly and splenic siderosis are well-known findings in beta-thalassemia major. We explored the relation between splenic size, splenic and hepatic siderosis in transfusion-dependent beta-thalassemic patients, assessed by MR imaging. Materials and methods: Abdominal MR imaging studies of 47 consecutive thalassemic patients and 10 healthy subjects, used as controls, were retrospectively reviewed. The signal intensity ratios of spleen and liver to the right paraspinous muscle (S/M, L/M, respectively) were calculated on T1, intermediate, and T2*-weighted gradient-echo sequences, splenic volume was estimated on axial images and serum ferritin levels were recorded. Results: Decreased S/M on all MR sequences was displayed in 36 patients. Six patients presented with normal S/M on all MR sequences and 5 patients displayed splenic hypointensity only on T2* sequence. No correlation between S/M and L/M was found whereas both L/M and S/M correlated with serum ferritin (P < 0.03). Splenic volume correlated to L/M (P < 0.05) but not to S/M values. Conclusion: In transfusion-dependent patients with beta-thalassemia, iron deposition in spleen cannot be predicted by the degree of hepatic siderosis, whereas splenomegaly relates to liver, but not splenic, iron overload. MR imaging can be a valuable tool in elucidating iron kinetics. © 2015, Springer Science+Business Media New York. Source

Purpose: To evaluate the impact of macular ischemia on the functional and anatomical outcome after intravitreal injections of ranibizumab for the treatment of diabetic macular edema (DME). Procedures: Participants were 49 patients with diabetes mellitus, divided into two groups based on the presence of ischemia on fluorescein angiography: (i) nonischemic group (n = 32) and (ii) ischemic group (n = 17). All patients were treated with intravitreal ranibizumab and were followed up for 6 months. The main outcome measures were changes in visual acuity (VA) and central foveal thickness (CFT). Results: There was a statistically significant improvement in VA and CFT between baseline and the end of the follow-up in the nonischemic group, while in the ischemic group there was no significant difference in VA but CFT differed significantly at the 6-month follow-up. Conclusions: Macular ischemia may have a negative impact on functional outcomes 6 months after intravitreal ranibizumab treatment in patients with DME but has no effect on anatomical outcomes. © 2014 S. Karger AG, Basel. Source

Discover hidden collaborations